Learn more about our ongoing COVID-19 response

Faculty and Staff Biography

 
Profile Photo

Kristine Griffett

Assistant Professor, Pharmacology
Center for Clinical Pharmacology
 

Education

B.S. Biology, St. Joseph's College, Patchogue, NY

M.S. Biology, C.W. Post - Long Island University, Brookville, NY

Ph.D. Genetics/Molecular Biology, University of South Florida, Tampa, FL

Specialty

Nuclear receptor pharmacology, molecular biology, drug discovery, metabolic disease, fatty liver disease, complications of diabetes, inflammatory pain, cardiovascular diseases

Current Research

My current research involves understanding the role of the Liver X Receptors in metabolic and cardiovascular diseases. These receptors are involved in the regulation of lipogenesis, cholesterol biosynthesis, gluconeogenesis, and inflammation, and have been validated targets for drug discovery in this area. Research involves mechanistic studies, next generation sequencing, cell-based assays, and in vivo models. This work is currently funded by the American Heart Association. Previous funding for this project from NIH NIDDK.

Other areas of interest include understand how the nuclear receptor REV-ERB regulates the inflammatory processes leading to chronic inflammatory pain, including diabetic peripheral neuropathy pain. These pain complications affect a majority of Americans. The goal is to understand the role of this receptor, validate it as a therapeutic target, and develop novel compounds to alleviate chronic inflammatory pain that are non-opioid treatments.

For the most up-to-date information on my research and lab news, please check out the lab site www.griffettlab.wordpress.com

Vita Highlights

Selected Publications:

  1. Griffett, K. and Burris, T.P. (2016) Promiscuous Activity of the LXR Antagonist GSK2033 in a Mouse Model of Fatty Liver Disease. Biochem and Biophys Res 479(3):424-428.1.

  2. Goher, S.S., Griffett, K., Hegazy, L., Elagawany, M., Arief, M.H., Avdagic, A., Banerjee, S., Burris, T.P., and Elgendy, B. (2018) Development of novel liver X receptor modulators based on a 1,2,4-triazole scaffold. Bioorganic and Medicinal Chemistry Letters.

  3. Sengupta, M., Griffett, K., Flaveny, C.A., and Burris, T.P. Inhibition of Hepatotoxicity by a LXR Inverse Agonist in a Model of Alcoholic Liver Disease. ACS Pharmacol. Transl. Sci. 1 (1): 50-60

  4. Flaveny, C.A., Griffett, K., El-Gendy, B.El-D.M., Kazantzis, M., Sengupta, M., Amelio, A.L., Chatterjee, A., Walker, J., Solt, L.A., Kamenecka, T.M., and Burris, T.P. (2015) Broad anti-tumor activity of a small molecule that selectively targets the Warburg effect and lipogenesis. Cancer Cell 28: 1-15.

  5. Griffett, K., Welch, R.D., Flaveny, C.A., Kolar, G.R., Neuschwander-Tetri, B.A., and Burris, T.P. (2015) The LXR Inverse Agonist SR9238 Suppresses Fibrosis in a Model of Non-Alcoholic Steatohepatitis, Molecular Metabolism. 4(4):353-357.

  6. Griffett, K and Burris, T.P. (2013) The Mammalian Clock and Chronopharmacology, Bioorganic and Medicinal Chemistry Letters. 23: 1929-34. PMID: 23481644.

  7. Griffett, K., Solt, L.A., El-Gendy, B.El-D.M., Kamenecka, T.M., and Burris, T.P. (2013). A Liver Selective LXR Inverse Agonist that Suppresses Hepatic Steatosis. ACS Chemical Biology, 8: 559-67. PMID: 23237488.